[HTML][HTML] Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma
O Hamid, C Robert, A Daud, FS Hodi… - … England Journal of …, 2013 - Mass Medical Soc
Background The programmed death 1 (PD-1) receptor is a negative regulator of T-cell
effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 …
effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 …
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 …
C Robert, A Ribas, JD Wolchok, FS Hodi, O Hamid… - The Lancet, 2014 - thelancet.com
Background The anti-programmed-death-receptor-1 (PD-1) antibody pembrolizumab has
shown potent antitumour activity at different doses and schedules in patients with …
shown potent antitumour activity at different doses and schedules in patients with …
[HTML][HTML] Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Background Patients with melanoma that progresses on ipilimumab and, if BRAF V600
mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed …
mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed …
Association of pembrolizumab with tumor response and survival among patients with advanced melanoma
Importance The programmed death 1 (PD-1) pathway limits immune responses to
melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody …
melanoma and can be blocked with the humanized anti-PD-1 monoclonal antibody …
Phase I study of pembrolizumab (MK-3475; anti–PD-1 monoclonal antibody) in patients with advanced solid tumors
A Patnaik, SP Kang, D Rasco, KP Papadopoulos… - Clinical cancer …, 2015 - AACR
Purpose: This phase I study evaluated the safety, maximum tolerated dose, antitumor
activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients with …
activity, and pharmacokinetics and pharmacodynamics of pembrolizumab in patients with …
[HTML][HTML] Evaluation of immune-related response criteria and RECIST v1. 1 in patients with advanced melanoma treated with pembrolizumab
FS Hodi, WJ Hwu, R Kefford, JS Weber… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose We evaluated atypical response patterns and the relationship between overall
survival and best overall response measured per immune-related response criteria (irRC) …
survival and best overall response measured per immune-related response criteria (irRC) …
[HTML][HTML] Programmed death-ligand 1 expression and response to the anti–programmed death 1 antibody Pembrolizumab in melanoma
AI Daud, JD Wolchok, C Robert, WJ Hwu… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker
for response and outcome after treatment with anti–programmed death 1 (PD-1). This study …
for response and outcome after treatment with anti–programmed death 1 (PD-1). This study …
Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001.
9005 Background: The anti–PD-1 antibody pembro is approved in the US for treating
unresectable or metastatic MEL that progressed following ipilimumab (IPI) and, if BRAF …
unresectable or metastatic MEL that progressed following ipilimumab (IPI) and, if BRAF …
Tumor-Agnostic Approvals: Insights and Practical Considerations
CC Lu, RA Beckman, XN Li, W Zhang, Q Jiang… - Clinical Cancer …, 2024 - AACR
Since the first approval of a tumor-agnostic indication in 2017, a total of seven tumor-
agnostic indications involving six drugs have received approval from the FDA. In this paper …
agnostic indications involving six drugs have received approval from the FDA. In this paper …
Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in …
KP Papadopoulos, KA Autio, T Golan, K Dobrenkov… - 2019 - ascopubs.org
9509 Background: Ligation of GITR on immune cells decreases Treg-mediated suppression
and enhances T cell proliferation. MK-4166 is a humanized IgG1 agonist monoclonal …
and enhances T cell proliferation. MK-4166 is a humanized IgG1 agonist monoclonal …